BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 23743853)

  • 1. Successful treatment of central nervous system PTLD with rituximab and cranial radiotherapy.
    Said-Conti V; Amrolia PJ; Gaze MN; Stoneham S; Sebire N; Shroff R; Marks SD
    Pediatr Nephrol; 2013 Oct; 28(10):2053-6. PubMed ID: 23743853
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Post-transplant lymphoproliferative disorder: a clinicopathologic study of 15 cases].
    Chen DB; Wang Y; Song QJ; Shen DH
    Zhonghua Bing Li Xue Za Zhi; 2012 Sep; 41(9):607-12. PubMed ID: 23157829
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Humanized anti-CD20 monoclonal antibody (Rituximab) treatment for post-transplant lymphoproliferative disorder.
    Ganne V; Siddiqi N; Kamaplath B; Chang CC; Cohen EP; Bresnahan BA; Hariharan S
    Clin Transplant; 2003 Oct; 17(5):417-22. PubMed ID: 14703923
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Post-transplant lymphoproliferative disorder--case reports of three children with kidney transplant.
    Spasojević-Dimitrijeva B; Peco-Antić A; Paripović D; Kruscić D; Krstić Z; Cupić M; Cvetković M; Milosevski-Lomić G; Kostić M
    Srp Arh Celok Lek; 2014; 142(1-2):83-8. PubMed ID: 24684038
    [TBL] [Abstract][Full Text] [Related]  

  • 5. EBV-positive post-transplant lymphoproliferative disorder presenting as primary diffuse large B-cell lymphoma of the central nervous system.
    Xu H; Rewerska J; Aardsma N; Slavin K; Valyi-Nagy T; Ni H
    Folia Neuropathol; 2017; 55(3):221-226. PubMed ID: 28984115
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Conservative management of post-transplant central nervous system lymphoma.
    Valavoor SH; Ashraf Z; Narwal R; Ratnam S
    Int Urol Nephrol; 2013 Aug; 45(4):1219-22. PubMed ID: 22476860
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rituximab therapy and reduction of immunosuppression to rescue graft function after renal posttransplantation lymphoproliferative disorder found by macrohematuria in a pancreas and kidney transplant recipient: a case report.
    Miyagi S; Sekiguchi S; Kawagishi N; Akamatsu Y; Satoh K; Takeda I; Fukushima D; Kobayashi Y; Tokodai K; Fujimori K; Satomi S
    Transplant Proc; 2011 Nov; 43(9):3299-301. PubMed ID: 22099782
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intrathecal therapy with rituximab in central nervous system involvement of post-transplant lymphoproliferative disorder.
    Czyzewski K; Styczynski J; Krenska A; Debski R; Zajac-Spychala O; Wachowiak J; Wysocki M
    Leuk Lymphoma; 2013 Mar; 54(3):503-6. PubMed ID: 22873830
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sequential treatment with rituximab followed by CHOP chemotherapy in adult B-cell post-transplant lymphoproliferative disorder (PTLD): the prospective international multicentre phase 2 PTLD-1 trial.
    Trappe R; Oertel S; Leblond V; Mollee P; Sender M; Reinke P; Neuhaus R; Lehmkuhl H; Horst HA; Salles G; Morschhauser F; Jaccard A; Lamy T; Leithäuser M; Zimmermann H; Anagnostopoulos I; Raphael M; Riess H; Choquet S; ;
    Lancet Oncol; 2012 Feb; 13(2):196-206. PubMed ID: 22173060
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Low viral load post-transplant lymphoproliferative disease localized within the tongue.
    Henry DD; Hunger SP; Braylan RC; Dharnidharka VR
    Transpl Infect Dis; 2008 Dec; 10(6):426-30. PubMed ID: 18657087
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Diffuse large B-cell lymphoma of the central nervous system in mycophenolate mofetil-treated patients with systemic lupus erythematosus.
    Tsang HH; Trendell-Smith NJ; Wu AK; Mok MY
    Lupus; 2010 Mar; 19(3):330-3. PubMed ID: 19897521
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of Primary Central Nervous System Posttransplant Lymphoproliferative Disorder in an Adult Kidney Transplant Recipient: A Case Report.
    Abbassi M; Riley R; Malkin M; Tang Y; Rajendran B; Yazbeck V
    Exp Clin Transplant; 2019 Feb; 17(1):111-114. PubMed ID: 28447926
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reduction of immunosuppression combined with whole-brain radiotherapy and concurrent systemic rituximab is an effective yet toxic treatment of primary central nervous system post-transplant lymphoproliferative disorder (pCNS-PTLD): 14 cases from the prospective German PTLD registry.
    Zimmermann H; Nitsche M; Pott C; Reinke P; Babel N; Hermann RM; Hauser IA; Hahn D; Ritgen M; Pietschmann C; Klapper W; Anagnostopoulos I; Trappe RU;
    Ann Hematol; 2021 Aug; 100(8):2043-2050. PubMed ID: 33973053
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Post-transplantation lymphoproliferative disorder in heart and kidney transplant patients: a single-center experience.
    Wasson S; Zafar MN; Best J; Reddy HK
    J Cardiovasc Pharmacol Ther; 2006 Mar; 11(1):77-83. PubMed ID: 16703222
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High-dose intravenous rituximab for multifocal, monomorphic primary central nervous system posttransplant lymphoproliferative disorder.
    Patrick A; Wee A; Hedderman A; Wilson D; Weiss J; Govani M
    J Neurooncol; 2011 Jul; 103(3):739-43. PubMed ID: 20872273
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Primary Cutaneous Polymorphic EBV-Associated Posttransplant Lymphoproliferative Disorder After a Renal Transplant and Review of the Literature.
    Ferguson NN; Thomas CP; Hohl RJ; Syrbu SI; Stone MS; Wanat KA
    Am J Dermatopathol; 2015 Oct; 37(10):790-4. PubMed ID: 25747810
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Epstein-Barr virus-positive post-transplant lymphoproliferative disorder of the central nervous system, after renal transplantation with a discrepancy in viral load between peripheral blood and cerebrospinal fluid.
    Boersma MN; van der Zanden A; Laverman GD; Sanders JS; de Vries PA
    Transpl Int; 2012 Nov; 25(11):e113-6. PubMed ID: 22909403
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intraventricular rituximab and systemic chemotherapy for treatment of central nervous system post-transplant lymphoproliferative disorder after kidney transplantation.
    Twombley K; Pokala H; Ardura MI; Harker-Murray P; Johnson-Welch SF; Weinberg A; Seikaly M
    Pediatr Transplant; 2012 Sep; 16(6):E201-9. PubMed ID: 22646132
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anti-CD20 monoclonal antibody (Rituximab) treatment for Epstein-Barr virus-associated, B-cell lymphoproliferative disease in pediatric liver transplant recipients.
    Serinet MO; Jacquemin E; Habes D; Debray D; Fabre M; Bernard O
    J Pediatr Gastroenterol Nutr; 2002 Apr; 34(4):389-93. PubMed ID: 11930095
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recurrent posttransplant lymphoproliferative disorder involving the larynx and trachea: case report and review of the literature.
    Banks CA; Meier JD; Stallworth CR; White DR
    Ann Otol Rhinol Laryngol; 2012 May; 121(5):291-5. PubMed ID: 22724273
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.